Introduction
============

Kidney cancer is a high-risk cancer that demonstrates a high mortality rate, accounting for an estimated 73,750 newly diagnosed cases and 14,830 cancer-related deaths in the United States in 2020 ([@ref-20]). Clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer, accounts for the majority of kidney cancer-related deaths ([@ref-19]). Localized RCC is commonly treated using nephrectomy and exhibits good prognosis; however, due to the resistance to traditional chemotherapy and radiotherapy, advanced RCC is considered a fatal malignancy with a poor overall survival (OS) ([@ref-19]). With the advances in tumor molecular genetics, the treatment for advanced RCC, in particular for metastatic RCC (mRCC), has evolved from traditional cytotoxic therapy to molecular targeted therapy, for example, sunitinib and everolimus, which have significantly prolonged the survival time for patients with RCC ([@ref-10]). However, the molecular targeted therapy for RCC remains limited due to the lack of molecular targets. Thus, there is an urgent requirement to further investigate the molecular mechanisms that drive RCC initiation and progression, which will help identify potential therapeutic targets and prognostic markers for RCC therapy.

Apart from the well-known von Hippel-Lindau (VHL) gene, genetic mutations in members of the PI3K/AKT/mTOR signaling pathway are also frequently observed in RCC, which promotes the hyperactivation of the PI3K/AKT/mTOR signaling cascade ([@ref-10]). The PI3K/AKT/mTOR signaling pathway, which is inhibited by phosphatase and tensin homolog (PTEN), is transduced through three checkpoint proteins or protein complexes: PI3K, AKT and mTOR. PTEN, PI3K, AKT and mTOR participate in the regulation of multiple biological functions, including cell survival, metabolism and tumorigenesis under context-specific physiological and pathological conditions ([@ref-2]; [@ref-7]). PTEN is a tumor suppressor gene, which is frequently mutated in tumors ([@ref-9]). PI3K consists of four isoforms: PIK3CA, PIK3CB, PIK3CD and PIK3CG. The activation of PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3), which subsequently recruits AKT to the plasma membrane, where AKT is activated by 3-phosphoinositide-dependent protein kinase (PDK) phosphorylation on Thr308. This process can be reversed by PTEN, a phosphatase that can transform PIP3 to inactivated PIP2. mTOR is a 289 kDa serine/threonine kinase that encompasses two functionally distinct protein complexes: mTOR complex 1 (mTORC1) and mTORC2 ([@ref-7]; [@ref-24]). Activated AKT phosphorylates mTORC1 on Ser2,448 to activate its kinase activity, which then leads to the activation of multiple anabolic biosynthetic pathways that control cell proliferation ([@ref-24]). PI3K/AKT/mTOR signaling pathway dysregulation is frequently identified in patients with RCC ([@ref-10]), and inhibitors of mTOR, including everolimus and temsirolimus, have proven efficacious in mRCC ([@ref-5]; [@ref-6]). In fact, previous studies have reported the prognostic value of PI3K/AKT/mTOR signaling pathway-related proteins; however, the majority of these studies were based on small-scale specimens and the conclusions lacked consistency ([@ref-8]; [@ref-11]; [@ref-12]; [@ref-14]; [@ref-15]; [@ref-18]; [@ref-28]). Thus, it is necessary to investigate the prognostic role of the PI3K/AKT/mTOR signaling pathway using large-scale databases.

By taking advantage of next-generation sequencing and multi-omics, a large number of potential biomarkers and therapeutic targets have emerged in recent years. The Cancer Genome Atlas (TCGA) ([@ref-10]), The Cancer Proteome Atlas (TCPA) ([@ref-13]), as well as several other large-scale cancer genome tools such as the Gene Expression Profiling Interactive Analysis (GEPIA) ([@ref-23]), the Kaplan--Meier (K-M) plotter ([@ref-21]) and the Human Protein Atlas (HPA) ([@ref-29]), have been comprehensively used to investigate the molecular profiles of several types of cancer. Nevertheless, only a few potentially useful prognostic biomarkers have been reported for RCC to date; for example, through screening the TCGA database, [@ref-10] discovered that numerous protein biomarkers, such as *fatty acid synthase (FASN)* and *AKT3* were prognostic factors for the survival of patients with ccRCC; and using the Oncomine and K-M plotter databases, our previous study reported that several mRNA biomarkers, such as *FASN* and *ATP citrate lyase (ACLY)*, may be prognostic factors for ccRCC ([@ref-26]). In the present study, the mRNA and some protein expression profiles of PI3K/AKT/mTOR signaling pathway members were compared between ccRCC and normal kidney tissues using the GEPIA, Oncomine and western blotting (WB) analyses, and their prognostic significance in ccRCC was subsequently systematically analyzed using the K-M plotter, HPA and TCPA databases ([Fig. 1](#fig-1){ref-type="fig"}). In addition, the correlation between these PI3K/AKT/mTOR signaling pathway members and specific clinicopathological parameters of cancer, such as cancer stage, was also explored. In conclusion, the present study provided a comprehensive overview of the OS biomarkers found in the PI3K/AKT/mTOR signaling pathway, which highlighted the potential role of this pathway in ccRCC progression and targeted therapy.

![A schematic diagram to investigate the expression and prognostic profiling of PI3K/AKT/mTOR signaling pathway members in ccRCC.](peerj-08-9261-g001){#fig-1}

Materials & Methods
===================

GEPIA analysis
--------------

The GEPIA server (<http://gepia2.cancer-pku.cn/>), which was based on the UCSC Xena project, was used to analyze the mRNA expression status of the following nine members of the PI3K/AKT/mTOR signaling cascade in ccRCC, as described previously ([@ref-23]): *PTEN, PI3K* (including *PIK3CA, PIK3CB, PIK3CD* and *PIK3CG*), *AKT* (including *AKT1, AKT2* and *AKT3*) and *mTOR*. Briefly, the mRNA expression data of 523 ccRCC and 100 normal kidney specimens from TCGA and Genotype-Tissue Expression (GTEx) were loaded into the server to analyze the differentially expressed genes between the two groups. The RNA-seq results were reported as the number of transcripts per million (TPM). The following filter indexes were set: expression mode was expression DIY, dataset was ccRCC, log-scale was log2 (TPM + 1), and *P*-value cut-off was 0.05. Then the mRNA expression parameters, including sample size and statistical box plot were displayed. For consistency analysis, the mRNA expression levels of the nine genes in 523 ccRCC and 72 matched normal specimens from TCGA, and their correlationship between the genes and the pathological stages in 523 ccRCC specimens were also analyzed.

Oncomine analysis
-----------------

The Oncomine database (<https://www.oncomine.org>) was used to validate the mRNA expression levels of the PI3K/AKT/mTOR pathway members, as previously described ([@ref-27]). After indexes were set: differential analysis (cancer versus normal tissue), cancer type (kidney cancer), and data type (mRNA), their differential expression parameters of the individual genes, such as sample size, *P*-value, fold changes and statistical box plot, were dispalyed.

WB analysis
-----------

All the patients signed the written informed consents before enrollment, and the procedures were approved by the ethical committees of The First Affiliated Hospital of Shandong First Medical University (No. 2017-S007). And 3 cases of ccRCC tissues (including cancer and adjacent non-cancerous), which were collected from 3 patients (2 males and 1 females, age from 54 to 65, Fuhrman nuclear grading with 1 G2 + 2 G3, TNM staging with 2 T1 + 1 T2) ([@ref-4]), were used for WB analysis as described previously ([@ref-25]). After incubated with the corresponding primary antibodies: anti-PI3K (1:1,000, rabbit, \#4249; Cell signaling Technology, Danvers, MA), anti-AKT (1:1,000, rabbit, \#4691; Cell signaling Technology, Danvers, MA), anti-mTOR (1:2,000, rabbit, ab2732; Abcam, Cambridge, MA), and anti-β-Actin (1:1,000, mouse, BM0627; BOSTER, Beijing, China), horseradish peroxidase (HRP) conjugated secondary antibodies (1:5,000, rabbit, SA00001-2 & mouse, SA00001-1; Proteintech, Wuhan, China) were used to detect the proteins. Then the blots were visualized by enhanced chemiluminescence (Amersham Imager 600, GE Healthcare, Marlborough, MA). Protein ladder (MAN0011772, Thermo Scintific, Waltham, MA) was used to label the corresponding proteins, and Image J software was used for quantification.

K-M plotter mRNA survival analysis
----------------------------------

The K-M plotter (<http://www.kmplot.com>), which contained the RNA-seq data from Gene Expression Omnibus (GEO), Cancer Biomedical Informatics Grid (caBIG) and TCGA, was used to analyze the correlation between the mRNA expression levels of each PI3K/AKT/mTOR signaling pathway member and the prognosis of patients with ccRCC (*n* = 530), as described previously ([@ref-21]). First, the filter indexes were set: the pathological type was ccRCC, and auto select best cut-off as the default cut-off. Then the nine PI3K/AKT/mTOR signaling pathway genes (*PTEN, PIK3CA, PIK3CB, PIK3CD, PIK3CG, AKT1, AKT2, AKT3* and *mTOR*) were loaded into the online server, and the K-M survival plots were used to identify their correlation with the OS for discovery analysis. The hazard ratio (HR), with 95% confidence intervals (CI), and the log-rank *P*-value were calculated automatically on the webpage after ≤150 months follow-up. The relationship between the gene expression levels and clinicopathological parameters, for example, sex, pathological stages and grades, of ccRCC, were also investigated.

HPA mRNA survival analysis
--------------------------

The HPA database (<http://www.proteinatlas.org>), which retrieved the RNA-seq data from the Genomic Data Commons (GDC) Data Portal, was used to validate the prognosis of PI3K/AKT/mTOR signaling pathway genes in patients with ccRCC ([@ref-29]). In the public database, the filter indexes were set: the pathological type was ccRCC, best expression cut-off as the default cut-off, then all the nine aforementioned genes were loaded into the database and the OS from the TCGA was used for validation analysis (*n* = 528). The K-M plot and log-rank *P*-value were also calculated accordingly after ≤150 months follow-up.

TCPA protein survival analysis
------------------------------

TCPA database (<https://tcpaportal.org/tcpa/>) was used to analyze the correlation between the PI3K/AKT/mTOR signaling pathway protein expression levels and the prognosis of patients with ccRCC ([@ref-13]). Briefly, seven proteins, including PTEN, PIK3CA, AKT, mTOR and three proteins modified by phosphorylation, phosphorylated (p)-AKT (S473), p-AKT (T308) and p-mTOR (S2448), were evaluated using TCPA database (*n* = 445) after ≤150 months follow-up. The log-rank and univariate Cox *P*-values were calculated automatically. The relationship between the protein expression levels and the clinicopathological parameters, for instance, the pathological stage and Fuhrman grade of ccRCC, were also investigated.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS 21.0 software (IBM Corp.). For GEPIA analysis, the mRNA expression levels of PI3K/AKT/mTOR signaling pathway members in ccRCC and normal tissues were analyzed using one-way ANOVA. For Oncomine and WB analyses, the PI3K/AKT/mTOR expression levels were analyzed using a two-tailed Student's *t*-test. For the K-M plotter and HPA analyses, the correlation between the mRNA expression levels and OS was calculated using K-M curves and the log-rank test. For TCPA analysis, the correlation between protein expression levels and OS was calculated using the log-rank test and a univariate Cox Proportional Hazards regression model. *P* \<0.05 were considered to indicate a statistically significant difference.

Results
=======

GEPIA, Oncomine and WB analyses of the expression levels of PI3K/AKT/mTOR signaling pathway members between ccRCC and normal tissues
------------------------------------------------------------------------------------------------------------------------------------

First, the mRNA expression profiles of the PI3K/AKT/mTOR signaling pathway members were analyzed using GEPIA as described previously ([@ref-23]). The RNA-Seq data from TCGA and GTEx were used to compare the expression levels of nine PI3K/AKT/mTOR signaling pathway members (*PTEN*, *PIK3CA*, *PIK3CB*, *PIK3CD*, *PIK3CG*, *AKT1*, *AKT2*, *AKT3* and *mTOR*) between ccRCC and normal kidney tissues. The mean mRNA expression levels of these genes were not significantly different between the 523 ccRCC and 100 normal tissues (*P* \> 0.05; [Fig. 2](#fig-2){ref-type="fig"}); however, both *PIK3CD* and *PIK3CG* displayed an upward trend while *mTOR* displayed a decreasing trend, but not significant expression levels in patients with ccRCC (*P* \> 0.05). Similar results were obtained between 523 ccRCC and 72 matched normal samples using GEPIA analysis ([Table S1](#supp-1){ref-type="supplementary-material"}).

![GEPIA mRNA expression profiles of PI3K/AKT/mTOR signaling pathway proteins in 523 ccRCC (T) and 100 normal ones (N), which was downloaded from TCGA and GTEx databases.\
Box plots demonstrate the relative mRNA expression levels (log2 (TPM+1)) of (A) *PTEN*, (B) *PIK3CA*, (C) *PIK3CB*, (D) *PIK3CD*, (E) *PIK3CG*, (F) *AKT1*, (G) *AKT2*, (H) *AKT3* and (I) *mTOR,* which were not significantly altered between the tissues (*P* \> 0.05).](peerj-08-9261-g002){#fig-2}

Regarding the association of mRNA expression with pathological stages of the ccRCC patients, the detailed expression levels of the PI3K/AKT/mTOR members were further investigated in the 523 patients using GEPIA. The violin plots showed their expression in each stage, which illustrated the mRNA expression levels of six genes, i.e., *PTEN* (*P* = 0.002), *PIK3CA* (*P* \< 0.001), *PIK3CB* (*P* = 0.010), *AKT1* (*P* \< 0.001), *AKT2* (*P* \< 0.001) and *AKT3* (*P* \< 0.001), were negatively correlated with their stages ([Fig. 3](#fig-3){ref-type="fig"}).

![GEPIA mRNA expression profiles of PI3K/AKT/mTOR pathway members in 523 ccRCC tissues, which investigated the association of their mRNA expression with pathological stages of ccRCC patients.\
Violin plots demonstrate the relationship between mRNA expression levels (log2 (TPM+1)) of (A) *PTEN*, (B) *PIK3CA*, (C) *PIK3CB*, (D) *PIK3CD*, (E) *PIK3CG*, (F) *AKT1*, (G) *AKT2*, (H) *AKT3* and (I) *mTOR*, which were not significantly altered between the tissues (*P* \> 0.05).](peerj-08-9261-g003){#fig-3}

Then Oncomine database (U133A/B microarray, 10 ccRCC and 10 matched normal kidney specimens) was used to validate their differential expression ([Table S2](#supp-2){ref-type="supplementary-material"}), which demonstrated that most of the PI3K/AKT/mTOR members were not significantly changed between ccRCC and normal specimens (*P* \> 0.05) except PTEN (1.77-fold increase in ccRCC, *P* \< 0.001), PIK3CA (1.56-fold increase, *P* = 0.010) and AKT1 (1.27-fold increase, *P* = 0.005).

Finally, further WB analysis displayed that the protein expression levels of PI3K, AKT and mTOR were not significantly changed between ccRCC and normal specimens (*P* = 0.774, *P* = 0.585, *P* = 0.480, respectively; [Fig. 4](#fig-4){ref-type="fig"}), which also consistent with the mRNA expression of PI3K/AKT/mTOR signaling members.

![Validation of PI3K, AKT and mTOR protein expression in ccRCC by WB.\
(A) WB for PI3K, AKT and mTOR expression of three individual ccRCC (T) and adjacent normal tissues (N). Actin as a loading control. (B) The statistic results of gray value ratios of the WB bands in ccRCC and normal tissues.](peerj-08-9261-g004){#fig-4}

K-M plotter and HPA prognostic analysis of the PI3K/AKT/mTOR signaling pathway members in ccRCC
-----------------------------------------------------------------------------------------------

For survival analysis, the public online resource K-M plotter was used to calculate the clinical significance of individual genes compared with OS in 530 patients with ccRCC ([Fig. 5](#fig-5){ref-type="fig"}; [Table 1](#table-1){ref-type="table"}). The results demonstrated that increased mRNA expression levels of *PTEN* \[HR 95% CI = 0.56 (0.41--0.75); *P* \< 0.001\] and *mTOR* \[HR 95% CI = 0.54 (0.38--0.78); *P* \< 0.001\] were associated with improved OS in patients with ccRCC. For the multiple *AKT* genes, *AKT3* \[HR 95% CI = 0.44 (0.32--0.62); *P* \< 0.001\] was observed to be a favorable factor; however *AKT1* \[HR 95% CI = 0.76 (0.56--1.02); *P* = 0.068\] and *AKT2* \[HR 95% CI = 1.34 (0.99--1.82); *P* = 0.055\] were not. As for the *PI3K* genes, the majority were identified as protective factors, including *PIK3CA* \[HR 95% CI = 0.52 (0.38--0.70); *P* \< 0.001\], *PIK3CB* \[HR 95% CI = 0.50 (0.37--0.68); *P* \< 0.001\] and *PIK3CG* \[HR 95% CI = 0.64 (0.47--0.87); *P* = 0.004\], whereas *PIK3CD* demonstrated the opposite effect \[HR 95% CI = 1.38 (1.01--1.91); *P* = 0.046\]. These results suggested that different members of AKT or PI3K may serve distinct roles in the prognosis of ccRCC.

![K-M plotter mRNA analysis displaying the overall survival curves of PI3K/AKT/mTOR signaling pathway members.\
The overall survival curves of (A) *PTEN*, (B) *PIK3CA*, (C) *PIK3CB*, (D) *PIK3CD*, (E) *PIK3CG*, (F) *AKT1*, (G) *AKT2*, (H) *AKT3* and (I) *mTOR* expression levels in 530 patients with clear cell renal cell carcinoma.](peerj-08-9261-g005){#fig-5}

In addition to investigating OS, cancer staging, sex and grading were further investigated to determine the correlation between mRNA expression levels and OS in ccRCC patients. According to the TNM staging system ([@ref-4]), the ccRCC samples were grouped into four stages and the correlation between mRNA expression levels and OS in different pathological stages of ccRCC patients was analyzed ([Table 2](#table-2){ref-type="table"}). It was observed that *PTEN, PIK3CA* and *PIK3CB* were positively correlated with a favorable OS in stage I, III and IV patients with ccRCC \[HR 95% CI = 0.46 (0.25--0.85) (stage I); 0.44 (0.25--0.79) (stage III); 0.51 (0.30--0.87) (stage IV) for *PTEN*; 0.48 (0.26--0.88) (stage I); 0.51 (0.29--0.89) (stage III); 0.61 (0.37--1.00) (stage IV) for *PIK3CA*; and 0.43 (0.23--0.81) (stage I); 0.40 (0.22--0.70) (stage III); 0.41 (0.25--0.67) (stage IV) for *PIK3CB*, respectively\]. Furthermore, increased *PIK3CG* expression level was correlated with an improved OS in stage I, II and III patients with ccRCC \[HR 95% CI = 0.53 (0.28--1.00); 0.29 (0.08--1.00); 0.31 (0.17--0.54), respectively\]. Similar results were achieved for *AKT3 and mTOR; AKT3* was found to be positively correlated with a favorable prognosis in stage III and IV patients with ccRCC \[HR 95% CI = 0.45 (0.25--0.81); 0.50 (0.27--0.94), respectively\] and the overexpression of *mTOR* was correlated with an improved OS in stage I and II patients with ccRCC \[HR 95% CI = 0.30 (0.12--0.77); 0.24 (0.06--0.86), respectively\]. *AKT1* was discovered to be a favorable factor in stage I \[HR 95% CI = 0.44 (0.24--0.80)\], whereas it found to be a poor factor in stage II and III patients with ccRCC \[HR 95% CI = 3.00 (0.98--9.20); 2.15 (1.14--4.07), respectively\]. *PIK3CD* mRNA expression levels were associated with a favorable OS in stage III \[HR 95% CI = 0.55 (0.31--0.96)\], but a worse OS in stage IV \[HR 95% CI = 2.42 (1.25--4.68)\] patients with ccRCC. *AKT2* mRNA expression was not correlated with the tumor stages of patients with ccRCC (*P* \> 0.05). These results suggested that the prognostic role of PI3K/AKT/mTOR signaling pathway members may be markedly influenced by TNM stages.

10.7717/peerj.9261/table-1

###### Correlation of the PI3K/AKT/mTOR mRNA expression with OS in ccRCC patients (K-M plotter, *n* = 530).

![](peerj-08-9261-g008)

  Protein   Gene     HR (95% CI)         *P-* value
  --------- -------- ------------------- ------------
  PTEN      PTEN     0.56 (0.41--0.75)   \<0.001
  PI3K      PIK3CA   0.52 (0.38--0.70)   \<0.001
            PIK3CB   0.50 (0.37--0.68)   \<0.001
            PIK3CD   1.38 (1.01--1.91)   0.046
            PIK3CG   0.64 (0.47--0.87)   0.004
  AKT       AKT1     0.76 (0.56--1.02)   0.068
            AKT2     1.34 (0.99--1.82)   0.055
            AKT3     0.44 (0.32--0.62)   \<0.001
  mTOR      mTOR     0.54 (0.38--0.78)   \<0.001

10.7717/peerj.9261/table-2

###### Correlation of the PI3K/AKT/mTOR mRNA expression with OS in different clinical stage of ccRCC patients (K-M plotter, *n* = 530).

![](peerj-08-9261-g009)

  Gene     Stage   n[^a^](#table-2fn1){ref-type="fn"}   HR (95% CI)          *P-* value
  -------- ------- ------------------------------------ -------------------- ------------
  PTEN     I       265                                  0.46 (0.25--0.85)    0.011
           II      57                                   3.28 (1.04--10.37)   0.034
           III     123                                  0.44 (0.25--0.79)    0.005
           IV      82                                   0.51 (0.30--0.87)    0.012
  PIK3CA   I       265                                  0.48 (0.26--0.88)    0.016
           II      57                                   2.08 (0.67--6.48)    0.200
           III     123                                  0.51 (0.29--0.89)    0.017
           IV      82                                   0.61 (0.37--1.00)    0.049
  PIK3CB   I       265                                  0.43 (0.23--0.81)    0.007
           II      57                                   2.14 (0.47--9.73)    0.310
           III     123                                  0.40 (0.22--0.70)    0.001
           IV      82                                   0.41 (0.25--0.67)    \<0.001
  PIK3CD   I       265                                  1.41 (0.74--2.70)    0.300
           II      57                                   2.25 (0.69--7.33)    0.170
           III     123                                  0.55 (0.31--0.96)    0.033
           IV      82                                   2.42 (1.25--4.68)    0.007
  PIK3CG   I       265                                  0.53 (0.28--1.00)    0.045
           II      57                                   0.29 (0.08--1.00)    0.046
           III     123                                  0.31 (0.17--0.54)    \<0.001
           IV      82                                   0.59 (0.34--1.03)    0.062
  AKT1     I       265                                  0.44 (0.24--0.80)    0.006
           II      57                                   3.00 (0.98--9.20)    0.044
           III     123                                  2.15 (1.14--4.07)    0.015
           IV      82                                   1.28 (0.78--2.10)    0.330
  AKT2     I       265                                  1.65 (0.91--2.99)    0.093
           II      57                                   2.22 (0.76--7.14)    0.130
           III     123                                  1.58 (0.90--2.78)    0.110
           IV      82                                   1.61 (0.96--2.68)    0.067
  AKT3     I       265                                  0.56 (0.31--1.02)    0.054
           II      57                                   0.43 (0.09--1.95)    0.260
           III     123                                  0.45 (0.25--0.81)    0.006
           IV      82                                   0.50 (0.27--0.94)    0.029
  mTOR     I       265                                  0.30 (0.12--0.77)    0.008
           II      57                                   0.24 (0.06--0.86)    0.018
           III     123                                  0.58 (0.33--1.02)    0.053
           IV      82                                   1.36 (0.82--2.26)    0.240

**Notes.**

The total number was 527, because there were missing expression values and/ or incomplete survival data.

Regarding the association of these genes with the sex of patients, the prognostic values of individual genes were further investigated in patients with ccRCC. As illustrated in [Table 3](#table-3){ref-type="table"}, *PTEN, PIK3CA, PIK3CB, PIK3CG* and *AKT3* were positively correlated with a favorable OS in both females \[HR 95% CI = 0.35 (0.21--0.59) for *PTEN*; 0.27 (0.15--0.51) for *PIK3CA*; 0.45 (0.27--0.76) for *PIK3CB*; 0.49 (0.30--0.82) for *PIK3CG*; and 0.32 (0.20--0.54) for *AKT3,* respectively\] and males \[HR 95% CI = 0.53 (0.36--0.77) for *PTEN*; 0.57 (0.39--0.82) for *PIK3CA*; 0.48 (0.33--0.70) for *PIK3CB*; 0.68 (0.47--0.99) for *PIK3CG*; and 0.48 (0.31--0.72) for *AKT3,* respectively\]. *mTOR* was positively correlated with an improved OS in female patients with ccRCC \[HR 95% CI = 0.27 (0.14--0.52)\], whereas *AKT2* was positively correlated with poor OS in males \[HR 95% CI = 1.71 (1.15--2.55)\]. Moreover, *PIK3CD* was positively correlated with a favorable OS in females \[HR 95% CI = 0.57 (0.34--0.97)\], but poor OS in male patients with ccRCC \[HR 95% CI = 1.81 (1.22--2.68)\]. These results suggested that sex may affect the prognostic role of PI3K/AKT/mTOR signaling pathway members in patients with ccRCC.

10.7717/peerj.9261/table-3

###### Correlation of the PI3K/AKT/mTOR mRNA expression with OS in different sex of ccRCC patients (K-M plotter, *n* = 530).

![](peerj-08-9261-g010)

  Gene     Sex      n     HR (95% CI)         *P*-value
  -------- -------- ----- ------------------- -----------
  PTEN     female   186   0.35 (0.21--0.59)   \<0.001
           male     344   0.53 (0.36--0.77)   \<0. 001
  PIK3CA   female   186   0.27 (0.15--0.51)   \<0. 001
           male     344   0.57 (0.39--0.82)   0.003
  PIK3CB   female   186   0.45 (0.27--0.76)   0.002
           male     344   0.48 (0.33--0.70)   \<0.001
  PIK3CD   female   186   0.57 (0.34--0.97)   0.037
           male     344   1.81 (1.22--2.68)   0.003
  PIK3CG   female   186   0.49 (0.30--0.82)   0.006
           male     344   0.68 (0.47--0.99)   0.044
  AKT1     female   186   0.51 (0.31--0.85)   0.008
           male     344   0.76 (0.49--1.17)   0.210
  AKT2     female   186   0.76 (0.46--1.25)   0.270
           male     344   1.71 (1.15--2.55)   0.007
  AKT3     female   186   0.32 (0.20--0.54)   \<0.001
           male     344   0.48 (0.31--0.72)   \<0.001
  mTOR     female   186   0.27 (0.14--0.52)   \<0.001
           male     344   0.78 (0.54--1.14)   0.200

Similarly, the prognostic value of the genes in different grades of ccRCC was also evaluated. As illustrated in [Table S3](#supp-3){ref-type="supplementary-material"} , the OS of the nine genes in different grades were consistent with the total OS.

For HPA validation analysis, the prognostic significance of the nine genes was examined, which found that the majority of genes demonstrated identical prognosis (OS) following the same follow-up period in another 528 patients with ccRCC ([Fig. 6](#fig-6){ref-type="fig"}). Specifically, increased expression levels of *PTEN* (*P* \< 0.001), *PIK3CA* (*P* \< 0.001), *PIK3CB* (*P* \< 0.001), *PIK3CG* (*P* = 0.004), *AKT3* (*P* \< 0.001) and *mTOR* (*P* = 0.001) were correlated with a significantly improved OS in 528 patients with ccRCC, whereas the overexpression of *PIK3CD* mRNA (*P* = 0.048) was significantly correlated with poor OS. *AKT1* mRNA expression levels demonstrated no significant correlation with the prognosis of patients with ccRCC (*P* = 0.082), with the K-M plotter results providing similar findings. In addition, HPA analysis identified *AKT2* as a hazard factor (*P* = 0.004), but it was not correlated with patients' prognosis (*P* = 0.055), which was assessed using K-M plotter analysis.

![HPA mRNA expression analysis displaying the overall survival curves of PI3K/AKT/mTOR signaling pathway members.\
The overall survival curves of (A) *PTEN*, (B) *PIK3CA*, (C) *PIK3CB*, (D) *PIK3CD*, (E) *PIK3CG*, (F) *AKT1*, (G) *AKT2*, (H) *AKT3* and (I) *mTOR* in 528 patients with clear cell renal cell carcinoma.](peerj-08-9261-g006){#fig-6}

TCPA prognostic analysis of the protein expression levels of PI3K/AKT/mTOR signaling pathway members in ccRCC
-------------------------------------------------------------------------------------------------------------

Since the activity of the PI3K/AKT/mTOR signaling cascade is largely regulated through phosphorylation events, the prognostic roles of core executors of the PI3K/AKT/mTOR signaling pathway, with or without phosphorylation, were investigated in patients with ccRCC. For this purpose, 445 cases of ccRCC from TCPA database were used for the statistical analysis ([Fig. 7](#fig-7){ref-type="fig"}; [Table 4](#table-4){ref-type="table"}). It was discovered that the higher expression levels of *PTEN* (log-rank *P* \< 0.001; Cox *P* \< 0.001), *p-AKT (S473*; log-rank *P* = 0.047; Cox *P* = 0.002) and *p-mTOR (S2448*; log-rank *P* = 0.004; Cox *P* \< 0.001) were associated with an improved OS in patients with ccRCC, which is consistent with previous findings ([@ref-24]). Although *AKT* and *mTOR* were not recognized as significant prognostic factors by K-M plot analysis (log-rank *P* = 0.263 for AKT; *P* = 0.543 for mTOR), they were identified as favorable prognostic factors by univariate Cox Proportional Hazards model analysis (Cox *P* = 0.003 for AKT; *P* = 0.041 for mTOR). However, PIK3CA and p-AKT (T308) expression levels were not correlated with tumor prognosis in patients with ccRCC (*P* \> 0.05).

![TCPA protein expression analysis displaying the overall survival curves of PI3K/AKT/mTOR signaling pathway members.\
The overall survival curves of (A) *PTEN*, (B) *PIK3CA*, (C) *AKT*, (D) *p-AKT* (T308), (E) *p-AKT* (S473), (F) *mTOR* and (G) *p-mTOR* (S2448) in 445 patients with clear cell renal cell carcinoma.](peerj-08-9261-g007){#fig-7}

As tumor staging and grading could markedly influence the statistical results of prognosis, correlation analysis between protein expression levels and ccRCC stages or grades were further performed ([Table 4](#table-4){ref-type="table"}). The expression levels of *PTEN, AKT* and *p-AKT (S473)* were positively correlated with both tumor stages (*P* \< 0.001; *P* = 0.045 and *P* \< 0.001, respectively) and tumor grades ( *P* \< 0.001; *P* \< 0.001 and *P* \< 0.001, respectively) in patients with ccRCC, which is consistent with previous studies ([@ref-10]). However, no significant correlation was observed between *PIK3CA, mTOR* and *p-mTOR (S2448)* expression and tumor stages or grades of patients with ccRCC (*P* \> 0.05).

Discussion
==========

ccRCC is the most prevalent kidney cancer; however, its molecular mechanism remains to be fully elucidated ([@ref-10]). The PI3K/AKT/mTOR signaling pathway, which is a central regulator of cell survival and proliferation, is constitutively active in RCC and reportedly implicated in RCC pathogenesis and progression. In the present study, the mRNA expression levels of the aforementioned nine genes demonstrated no significant differences between ccRCC and normal tissues (*P* \> 0.05), suggesting that the activation of the PI3K/AKT/mTOR signaling pathway in patients with ccRCC may not be dependent on their transcriptional regulation. Although WB displayed an upward trend of AKT protein expression in ccRCC, more samples were needed to clarify this issue. When striatified by clinical stage of the 523 ccRCC cases using GEPIA, the mRNA expression levels of six genes, i.e., *PTEN*, *PIK3CA*, *PIK3CB*, *AKT1*, *AKT2* and *AKT3*, were negatively correlated with their stages (*P* \< 0.05). Further prognostic analysis using the K-M plotter and HPA demonstrated that the mRNA expression levels of the major PI3K/AKT/mTOR signaling pathway members (*PTEN, PIK3CA, PIK3CB, PIK3CG, AKT3* and *mTOR*) were positively correlated with a favorable OS in patients with ccRCC, whereas *PIK3CD* mRNA expression levels were positively correlated with a poor OS (*P* \< 0.05). Accordingly, TCPA analysis demonstrated that the protein expression levels of PTEN, p-AKT (S473*)* and p-mTOR (S2448) were correlated with an improved OS (*P* \< 0.05). The relationship between their mRNA or protein expression levels and several clinicopathological features, such as sex, pathological stage and Fuhrman grade, were also analyzed. The results demonstrated that the majority of the stratified prognosis was consistent with the overall prognosis, which confirmed the validity of our conclusion. In general, the prognosis between the mRNA and protein expression levels of members of the PI3K/AKT/mTOR signaling pathway was consistent, with the majority being recognized as favorable prognostic factors in patients with ccRCC. The mRNA expression levels of the six genes, i.e., *PTEN*, *PIK3CA*, *PIK3CB*, *AKT1*, *AKT2* and *AKT3*, were negatively correlated with their stages, which was also consistent with their favorable prognosis in ccRCC. This suggested that the function of PI3K/AKT/mTOR in ccRCC was not only dependent on the mRNA and protein expression levels, but also reliant on protein activation through phosphorylation, such as *p-AKT* and *p-mTOR*. What's more, it also indicated that the activation of PI3K/AKT/mTOR was a complicated process, and further molecular biological, pathological and biochemical experiments were needed to support the prognosis of PI3K/AKT/mTOR pathway members in ccRCC. To the best of our knowledge, this was the first report studying the prognostic role of mRNA and protein expression levels of multiple PI3K/AKT/mTOR pathway members, such as *PTEN, AKT1* and *mTOR*, in ccRCC simultaneously. Our findings indicated that they may be potential prognostic markers for ccRCC, in addition to suggesting that PI3K/AKT/mTOR pathway signaling abnormalities may be involved in ccRCC tumorigenesis and progression.
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###### Correlation of the PTEN/PI3K/AKT/mTOR protein expression with OS in ccRCC patients (TCPA, *n* = 445).

![](peerj-08-9261-g011)

  Protein   Subgroup        Log-rank *P*   Cox *P*[^a^](#table-4fn1){ref-type="fn"}   Stage     Grade
  --------- --------------- -------------- ------------------------------------------ --------- ---------
  PTEN      PTEN            \<0.001        \<0.001                                    \<0.001   \<0.001
  PI3K      PIK3CA          0.456          0.834                                      0.720     0.816
  AKT       AKT             0.263          0.003                                      0.045     \<0.001
            p-AKT(S473)     0.047          0.002                                      \<0.001   \<0.001
            p-AKT(T308)     0.848          0.204                                      0.475     0.240
  mTOR      mTOR            0.543          0.041                                      0.272     0.056
            p-mTOR(S2448)   0.004          \<0.001                                    0.062     0.147

**Notes.**

Abbreviation for univariate Cox *P*.

The PI3K/AKT/mTOR signaling pathway serves an important role in ccRCC pathogenesis and progression, and is negatively regulated by the tumor suppressor *PTEN*. *PTEN* has been identified as one of the most commonly lost or mutated tumor suppressor genes in human cancers ([@ref-17]; [@ref-22]); however, although *PTEN* has been thoroughly investigated in RCC, its prognostic role remains controversial. For example, [@ref-28] reported that *PTEN* protein expression levels were decreased in RCC, and *PTEN* could be used as a favorable prognostic (OS) marker, whereas [@ref-11] discovered that *PTEN* was not an independent prognostic marker of RCC. However, two meta-analyses indicated that *PTEN* was a favorable prognostic factor for patients with ccRCC ([@ref-17]; [@ref-22]), which is consistent with our findings. In recent years, research has also focused on investigating the prognosis of other PI3K/AKT/mTOR signaling pathway proteins using immunohistochemistry analysis. For example, [@ref-15] demonstrated that *PI3K* activation was inversely correlated with RCC patients' survival, and that low *PTEN*/high *p-AKT* expression levels were also associated with a decreased survival in 176 patients with RCC; [@ref-16] found that high expression levels of nuclear *p-AKT (S473)* were associated with favorable disease-specific survival (DSS) in 375 patients with RCC; and [@ref-8] reported that increased *p-AKT (S473)* expression levels were correlated with a poorer OS for 440 patients with RCC. In addition, [@ref-12] investigated the expression levels of *mTOR* and *p*-*mTOR* (S2448) in 10 ccRCC and normal kidney tissues, and found that p-*mTOR* (S2448), but not mTOR expression levels, were increased in ccRCC. A subsequent study by the same authors comprehensively investigated the differential expression levels of mTOR and p-mTOR in 342 primary and 90 metastatic ccRCC tissues, and revealed that high p-mTOR expression levels, but not mTOR levels, were associated with impaired OS ([@ref-18]). Furthermore, [@ref-14] reported that post-treatment, the combination of increased p-mTOR expression levels and low VEGF expression levels was negatively correlated with OS in 79 patients with mRCC who were refractory to first-line sunitinib treatment. However, collectively these studies failed to reach a consistent conclusion and the prognostic role of the PI3K/AKT/mTOR signaling pathway in RCC remains controversial. The prognostic inconsistency of the PI3K/AKT/mTOR signaling pathway in RCC may be due to the remarkable heterogeneity of RCC specimens, the limited sample size and the divergence of clinicopathological backgrounds.

Integrated bioinformatics analysis confirmed that the PI3K/AKT/mTOR pathway was activated in ccRCC, but the prognostic significance was not fully elucidated ([@ref-1]; [@ref-3]; [@ref-10]; [@ref-24]). Through pan-cancer proteogenomic atlas analysis, [@ref-24] found that PTEN, p-AKT and p-mTOR expression levels were all significantly correlated with improved outcomes in 32 major types of cancer, which was also observed in the present study. Similar results were reported by Han, who demonstrated that certain members of the PI3K/AKT/mTOR signaling pathway, such as PTEN protein expression, and PTEN and AKT3 mRNA expression were prognostic factors for ccRCC ([@ref-10]). However, no clarification was provided on whether these were associated with a favorable or unfavorable prognosis ([@ref-10]). In addition, in 446 ccRCC cases, integrative proteogenomic analysis revealed that some members of the PI3K/AKT/mTOR signaling pathway, for example, PTEN and AKT mRNA expression levels, and PTEN protein expression levels, were recognized as favorable predictors for ccRCC ([@ref-1]), which was also consistent with our findings in the present study. Meanwhile, through multilevel genomics-based taxonomy of 894 RCC samples, [@ref-3] demonstrated that the PI3K/AKT/mTOR signaling pathway could distinguish between RCC subtypes, such as clear cell, chromophobe and papillary RCC; however the prognostic value was not investigated. In the present study, comprehensive analysis of the prognostic significance of components of this pathway at the mRNA and protein level was performed in ∼500 ccRCC tissues using the K-M plotter, HPA and TCPA databases; it was found that the majority of the mRNAs (such as *PTEN* and *AKT3*) and several proteins \[such as *PTEN* and *p-AKT (S473)* \] were favorable prognostic factors for ccRCC, which indicated that the PI3K/AKT/mTOR signaling pathway may be implicated in ccRCC progression, which may also provide a potential therapeutic target for patients with ccRCC. These findings are contradictory to the common knowledge that the PI3K/AKT/mTOR signaling pathway promotes the initiation and progression of RCC. However, mTOR signaling is necessary for multiple biological effects, including energy metabolism homeostasis, autophagy, cell survival and apoptosis. Thus, the prognostic roles of PI3K/AKT/mTOR signaling pathway members in patients with RCC may be different under specific physiological or pathological conditions, although this hypothesis requires to be further investigated.

Conclusions
===========

The present study investigated the mRNA expression profiles of multiple PI3K/AKT/mTOR signaling pathway components, including *PTEN*, *PIK3CA*, *PIK3CB*, *PIK3CD*, *PIK3CG*, *AKT1*, *AKT2*, *AKT2* and *mTOR*, in ccRCC and normal tissues using GEPIA and Oncomine analyses, and detected PI3K, AKT and mTOR protein expression using WB analysis. The prognostic significance of these genes and proteins in ccRCC patients was evaluated using K-M plotter, HPA and TCPA analysis, which suggested that several members of the PI3K/AKT/mTOR signaling pathway, especially *PTEN*, may be favorable prognostic factors in ccRCC. To the best of our knowledge, our study was the first to reveal the detailed OS of nine PI3K/AKT/mTOR signaling pathway members simultaneously. These results further suggested that the PI3K/AKT/mTOR signaling pathway may be implicated in ccRCC initiation and progression, and that components could be used as potential therapeutic targets in ccRCC.
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###### GEPIA box plots of the mRNA expression profiles of PI3K/AKT/mTOR signaling pathway proteins in 523 clear cell renal cell carcinoma (T) and 72 normal kidney tissues (N)
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Click here for additional data file.
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###### Oncomine box plots of the mRNA expression profiles of PI3K/AKT/mTOR pathway members in 10 clear cell renal cell carcinoma (T) and 10 matched normal kidney tissues (N)

###### 

Click here for additional data file.
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###### Correlation of the PI3K/AKT/mTOR mRNA expression with OS in different pathological grade of ccRCC patients (K-M plotter, *n* = 530)
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Click here for additional data file.
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###### WB raw data

###### 

Click here for additional data file.
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###### [Fig. 4B](#fig-4){ref-type="fig"} raw data
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Click here for additional data file.

10.7717/peerj.9261/supp-6

###### [Fig. 2](#fig-2){ref-type="fig"} (GEPIA mRNA) raw data
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Click here for additional data file.
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###### Detailed gel blots of PI3K, AKT, Actin and mTOR
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Click here for additional data file.
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